In a recent paper in PNAS, Rigoutsos et al. (2006) describe a nonrandom pattern of repeated elements, called pyknons, which are found more frequently in the 3′ untranslated regions of genes than in other regions of the human genome. Although it is unclear how pyknons might have arisen, it is possible that they may be involved in a new form of gene regulation.
Toll-like receptors (TLRs) recognize microbial products and initiate a complex immune response designed to eliminate invading pathogens. A key structural motif involved in the signal transduction of TLRs is the Toll/IL-1 receptor (TIR) domain (reviewed in Dunne and O'Neill, 2003) . TIR domains can be found in the cytoplasmic portions of all TLRs, the IL-1 receptor family, and a group of adaptor proteins. This latter group includes myeloid differentiation factor 88 (MyD88); TIR-domain-containing adaptor protein (TIRAP), also called MyD88 adaptor-like (Mal); TIRdomain-containing adaptor inducing interferon-β (TRIF), also called TICAM-1; and TRIF-related adaptor molecule (TRAM), or TICAM-2. Although nearly all TLRs recruit MyD88, only some recruit TIRAP, TRIF, and TRAM, giving rise to specificity in signaling. In this issue, Kagan and Medzhitov (2006) provide fresh insights into how TIRAP and MyD88 are recruited to TLR4 in the plasma membrane.
MyD88 activates the serine/threonine IRAK kinases IRAK1 and IRAK4. The IRAKs then enable the recruitment and activation of tumor necrosis factor receptor-associated factor 6 (TRAF-6), a RING-domain ubiquitin ligase that activates the TAK1 kinase through polyubiquitination (reviewed in Chen, 2005 ). TAK1 in turn activates the IKK complex, which phosphorylates IκBs (NF-κB inhibitors) and targets them for ubiquitination and subsequent degradation. This releases NF-κB, which moves to the nucleus and regulates its target genes, including those that encode proinflammatory cytokines. It has been demonstrated that both TIRAP and MyD88 are required for activation of the NF-κB pathway in response to signaling through TLR2 and TLR4, whereas only MyD88 is required for other TLRs and the IL1R. The mechanism by which TIRAP is specifically required for TLR2 and TLR4 signaling was not understood.
In the new study, Kagan and Medzhitov (2006) found that TIRAP contains a phosphatidylinositol 4,5-bisphosphate (PIP2) binding domain that targets this adaptor to discrete regions of the plasma membrane. Mutations in the PIP2 binding domain of TIRAP-or the hydrolysis of cellular PIP2 by bacterial PIP2 phosphatases-abrogated the recruitment of TIRAP to the plasma membrane as well as its ability to induce cytokines in response to lipopolysaccharide (LPS, a component of the bacterial cell wall). Furthermore, when the PIP2 binding domain of TIRAP was replaced with the PH domain of PLCδ1, which also binds to PIP2, the chimeric protein was capable of restoring TLR4 signaling in TIRAPdeficient cells. In contrast, when TIRAP was mislocalized to other membrane compartments, it failed to support TLR4 signaling. Interestingly, when TIRAP was targeted to the plasma membrane through a PIP2-independent membrane-targeting sequence (SH4 domain of Fyn), it could not complement TLR4 signaling, suggesting that targeting of TIRAP to a specialized PIP2-containing domain of the plasma membrane is important for its signaling function. TIRAP is delivered to the plasma membrane from the endosome through a mechanism that depends on the ARF6 GTPase.
Why is localization of TIRAP to the plasma membrane important for TLR4 signaling? It turns out that the sole function of TIRAP is to recruit MyD88 to the plasma membrane ( Figure 1 ). Both TIRAP and MyD88 contain TIR domains that allow them to interact. In cells containing TIRAP mutants that fail to localize to the PIP2-containing membrane, MyD88 is not recruited to the plasma membrane. Remarkably, when MyD88 was fused to the PIP2-targeting sequence of PLCδ1 (which allows it to localize directly to the plasma membrane), this fusion protein completely restored LPS signaling in cells lacking TIRAP as well as those lacking both TIRAP and MyD88. The same fusion protein, however, failed to rescue IL-1β signaling in cells lacking both Upon recognition of microbial products, Toll-like receptors (TLRs) recruit distinct combinations of adaptors to induce TLR-specific gene expression. In this issue, Kagan and Medzhitov (2006) demonstrate that the adaptor TIRAP/Mal localizes to the plasma membrane by binding to phosphatidylinositol 4,5-bisphosphate (PIP2). This binding recruits a key adaptor MyD88 to TLR4, suggesting that there is crosstalk between the TLR signaling pathway and phospholipid metabolism.
Sorting out Toll Signals
TIRAP and MyD88, suggesting that the IL-1β receptor and TLR4 signal from distinct domains in the plasma membrane.
The obligatory requirement for targeting TIRAP and MyD88 to PIP2-containing membranes raises the interesting possibility that TLR signaling may be regulated by phospholipid metabolism (Figure 1) . Growth factors and integrin signaling are known to regulate the production of PIP2 (McLaughlin et al., 2002) . It has been shown previously that macrophages lacking the integrin CD11b are less responsive to LPS (Flo et al., 2000; Perera et al., 2001 ), but the mechanism has not been elucidated. The study by Kagan and Medzhitov (2006) now provides a mechanism that links this integrin to TLR4 signaling. They demonstrated that the plasma-membrane localization of TIRAP and LPS-induced production of the proinflammatory cytokine IL-6 were severely impaired in CD11b-deficient macrophages, whereas the induction of chemokines through the TIRAP-independent pathway was intact in the absence of CD11b. It will be interesting to determine whether other signaling pathways that regulate PIP2 metabolism also affect TLR2 and TLR4 signaling. If so, antagonists of PIP2 production may be used to treat inflammatory diseases caused by aberrant activation of TLRs.
The Kagan and Medzhitov (2006) study represents a major advance in the mechanistic understanding of TLR signaling. Like many other important discoveries, the role of PIP2 in TLR4 signaling also raises important questions that await further research. One question is whether PIP2 simply recruits TIRAP and subsequently MyD88 to the plasma membrane or whether this phospholipid has additional roles. Since only the PIP2 binding domain, but not another plasmamembrane-targeting domain (e.g, the SH4 domain), endows the ability of TIRAP to recruit MyD88 to the plasma membrane, it is possible that PIP2 may act as an allosteric regulator. Alternatively, as PIP2 is present in the endosomal membrane, MyD88 may have to be recruited to the endosomal membrane before it can move together with TIRAP to the plasma membrane.
Another important question is whether a pool of endogenous MyD88 is constitutively associated with TIRAP at the plasma membrane or whether the recruitment of MyD88 to the membrane is induced by TLR4 signaling. As TIRAP appears to be localized constitutively at the plasma membrane and contains a TIR domain that can associate with the TIR domain of MyD88, it is possible that the pool of MyD88 that mediates TLR4 signaling is already in the vicinity of TLR4. The engagement of TLR4 may lead to the oligomerization of the cytosolic TIR domain or a conformational change of this domain that allows the recruitment of MyD88. Alternatively, the recruitment of MyD88 to the plasma membrane may require both TIRAP and the engagement of TLR4. These possibilities can be distinguished by visualizing the trafficking of endogenous MyD88 following LPS treatment.
The regulation of adaptors through membrane tethering is not restricted to TIRAP. In fact, a recent study from Golenbock and colleagues (Rowe et al., 2006) found that the related adaptor TRAM contains an N-terminal myristoylation site that is responsible for targeting TRAM to the plasma membrane, where it colocalizes with TLR4. Mutations in the N-myristoylation sequence of TRAM abrogated the membrane localization of TRAM as well as its ability to induce cytokines in response to LPS. TRAM acts exclusively in the TLR4 pathway (Fitzgerald et al., 2003; Yamamoto et al., 2003) . In addition to the activation of NF-κB signaling via TIRAP and MyD88, TLR4 also activates a MyD88-independent response resulting in the activation of interferon (IFN) regulatory factor 3 (IRF3) and the induction of type-I IFNs, as well as a delayed NF-κB response (Figure 1 ). TRIF is critical for these MyD88-independent responses. Membrane localization of TRAM functions to recruit and activate TRIF, which engages the downstream kinase TBK1 to activate IRF3 and induce IFN gene transcription. In contrast to TLR4 signaling, TLR3 recruits TRIF directly to engage the IRF3 and NF-κB pathways. The emerging theme from these recent studies is that TLR4 has evolved to employ the sorting adaptors TIRAP and
Figure 1. The Sorting and Signaling Adaptors in TLR4 Responses
β2 integrin signaling (e.g., CD11b) regulates PIP2 production via ARF6 and PI5K. TIRAP/Mal contains a PIP2 binding domain, which facilitates its recruitment to the plasma membrane and association with TLR4. TLR4 and the coreceptor MD2 bind LPS, and this binding triggers the recruitment of TIR-domain-containing adaptors to the receptor complex. TIRAP functions as a "sorting adaptor" to recruit the "signaling adaptor" MyD88. MyD88 engages downstream IRAK kinases and the TRAF6 ubiquitin ligase to propagate signals to NF-κB and AP-1 transcription factors. Analogous to TIRAP, TRAM-which is localized to the plasma membrane through N-terminal myristoylation (Myr)-functions as a sorting adaptor to recruit its signaling adaptor TRIF. TRIF engages TANK binding kinase 1 (TBK1), leading to IRF3 activation. There is also crosstalk between the TRAM-TRIF and TIRAP-MyD88 pathways for the regulation of NF-κB and inflammatory cytokines. Rigoutsos et al. (2006) divided the human genome into genic and nongenic regions and looked for patterns of at least 16 bases in length that occurred at least 40 times in the nongenic portion. They removed patterns that did not occur at least once in the genic regions and filtered the remaining patterns so that all genic instances were nonoverlapping. There were 127,998 of these patterns, far more than one would expect to appear by chance. They called these sequence patterns pyknons from the Greek word meaning "dense." Interestingly, these pyknons are found more often in the 3′ untranslated regions (UTRs) of genes than in other regions of the genome (7.33% nucleotide coverage compared to 3.04% in exons) (Figure 1 ). The spacing of pyknons in 3′ UTRs is also suggestive, with the average inter-pyknon distance falling between 18 and 22 nucleotides. Rigoutsos et al. (2006) suggest that this finding hints at the possibility of complex posttranscriptional regulation events, such as those mediated by miRNAs. Small regulatory RNA sequences are typi-
